CHRS — Coherus Oncology, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1512762 ·
Last close
$0.48
Market Cap
$73.95M
52W High
$2.62
52W Low
$0.43
ADV30
2,183,633
Next earnings
2026-11-09
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 14,307,000 10,065,000 -32,331,000 -20,631,000 191,183,000 82,923,000 130,345,000
Mar 2026 12,310,000 8,496,000 -36,151,000 -38,327,000 266,022,000 115,238,000 187,399,000
Dec 2025 12,748,000 8,703,000 -45,880,000 -37,643,000 258,343,000 88,879,000 197,329,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-173,711,000
Investing CF
$49,839,000
Financing CF
$73,861,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.97
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,481,261,000
Inventory
$4,824,000
Receivables
$13,916,000
ST Investments
$30,142,000
EBIT TTM
$-145,965,000
Pretax Income TTM
$-155,504,000
Interest Exp TTM
$9,539,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$53,639,000
EBITDA
$-141,919,008
Free Cash Flow
$-139,939,744
Enterprise Value
$67,129,864
Total Cash
$83,629,000
Total Debt
$69,549,000
Shares Out
154,538,277
Trailing EPS
$-1.12
Book Value
$0.16
ROE
-275.2%
ROA
-26.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 42,172,000 -181,134,000 168,024,000 258,343,000 197,329,000 61,014,000 -138,513,000
Dec 2024 26,389,000 -199,653,000 28,507,000 448,533,000 580,523,000 -131,990,000 -20,440,000
Dec 2023 257,244,000 -203,199,000 -237,892,000 629,604,000 823,029,000 -193,425,000 -174,884,000
Dec 2022 211,042,000 -256,880,000 -291,754,000 480,847,000 618,265,000 -137,418,000 -241,124,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$50,936,000
NetIncome TTM
$-132,132,000
OpCashFlow TTM
—
Assets (Latest)
$191,183,000
Forward EPS
$-0.63

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $0.50 · spot: $0.41 · call volume: 4 · put volume: 3
Expected Move to 2027-05-21: ±$0.34 (82.93%) — implied range $0.07 – $0.75 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TNYA Tenaya Therapeutics, Inc. $73.58M $0.32 —
CLLS Cellectis S.A. $77.08M $1.06 —
AVXL ANAVEX LIFE SCIENCES CORP. $68.60M $0.74 —
ATRA Atara Biotherapeutics, Inc. $66.22M $6.50 —
BDTX Black Diamond Therapeutics, Inc. $82.75M $1.44 —

News headlines (Yahoo Finance, 1h cache)

Here's Why Coherus Oncology (CHRS) Is a Great 'Buy the Bottom' Stock Now
2026-11-18 13:55 · Yahoo
ONCY: Supply Agreement with Coherus to Evaluate Pelareorep in SCAC with Checkpoint Inhibitor
2026-11-16 13:05 · Yahoo
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
2026-11-13 17:10 · Yahoo
Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround
2026-11-13 13:35 · Yahoo
Coherus Oncology Inc (CHRS) (Q3 2026) Earnings Call Highlights: Cost Cuts, Loqtorzi Growth and ...
2026-11-10 15:04 · Yahoo
Coherus Oncology, Inc. Q3 2026 Earnings Call Summary
2026-11-10 13:30 · Yahoo
Coherus Oncology: 3 Key Takeaways for Long-Term Investors
2026-11-10 08:10 · Yahoo
Coherus Oncology (CHRS) Q3 2026 Earnings Call Transcript
2026-11-10 07:48 · Yahoo
What Coherus Oncology (CHRS) Said on Its Q3 Earnings Call
2026-11-10 01:14 · Yahoo
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
2026-11-09 22:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.